Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs
Journal of Veterinary Pharmacology and Therapeutics · 2025
DOI: 10.1111/jvp.13510 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2025. Verfasst von Yishan Kuo und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA. Hauptthemen laut MEDLINE: Triazoles, Pyridines, Nitriles, Antifungal Agents. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wayne D. and Josephine H. Spangler Endowment Fund through the University of Illinois Urbana-Champaign, College of Veterinary Medicine, Brasley Small Animal Clinic Fund through the University of Illinois Urbana-Champaign, College of Veterinary Medicine.
Abstract (Originalsprache)
Isavuconazole, a triazole antifungal used in humans for invasive fungal infections, may be effective for treating canine fungal infections, although data on its use in dogs is limited. This study aimed to determine the pharmacokinetics and safety of a single dose of isavuconazole in dogs, administered both intravenously and orally. Six healthy dogs received 186 mg isavuconazonium sulfate in a crossover design, with blood samples collected over 28 days and an 8‐week washout period. Plasma isavuconazole and isavuconazonium concentrations were measured by liquid chromatography/mass spectrometry, and pharmacokinetic parameters were determined by non‐compartmental analysis. Isavuconazole was well tolerated, with key findings including intravenous clearance at 350 ± 112 mL/kg/h, volume of distribution at steady state at 9.8 ± 4.5 L/kg, and a terminal half‐life of 90 ± 44 h. For oral administration, the maximum concentration was 0.60 ± 0.27 μg/mL, time to maximum concentration was 6.73 ± 2.45 h, terminal half‐life was 125 ± 80 h, and the area under the curve was 7.44 ± 2.39 μg h/mL. Oral bioavailability was 81.4% ± 12.8%. These results suggest isavuconazole has a long half‐life in dogs and is well absorbed orally when administered in the fasted state. Further studies are warranted to establish a therapeutic regimen in dogs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Veterinary Clinical Medicine, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
- The Duke Proteomics and Metabolomics Core Facility, Duke University, Durham, North Carolina, USA.
ORCID-Profile: Yishan Kuo, Jennifer M Reinhart
Förderung
- Wayne D. and Josephine H. Spangler Endowment Fund through the University of Illinois Urbana-Champaign, College of Veterinary Medicine
- Brasley Small Animal Clinic Fund through the University of Illinois Urbana-Champaign, College of Veterinary Medicine
Zitieren
APA
Kuo, Y., Li, Z., Forsythe, L. E., & Reinhart, J. M. (2025). Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13510
Vancouver
Kuo Y, Li Z, Forsythe LE, Reinhart JM. Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs. Journal of Veterinary Pharmacology and Therapeutics. 2025. doi:10.1111/jvp.13510
BibTeX
@article{Kuo2025,
author = {Kuo, Yishan and Li, Zhong and Forsythe, Lauren E and Reinhart, Jennifer M},
title = {Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2025},
doi = {10.1111/jvp.13510}
}
EUVIMED